Real‐world safety and effectiveness of retreatment of Egyptian chronic hepatitis C patients not responding to NS5A inhibitor‐based therapies

Yousif, Monkez M; Ahmed, Hussien; Elsadek, Hany M.; Gouda, Tamer M.; Elsayed, Islam; Shendi, Ali; Magdy, Mahmoud; lbrahim, Nevin F.; Sadek, Ayman Magd Eldin Mohammad; Zaki, Ayman; Shafeik, Hamdy; Zahran, Mahmoud

doi:10.1111/jvh.13349

Cited by 3 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overall SVR rates in the two groups were 98. 1% [136]. In another study, patients who failed SOF/DCV were retreated successfully with other DAAs [137].…”

Section: Daa Treatment Failuresmentioning

confidence: 98%

Liver Transplantation and HCV Genotype 4

Alghamdi¹,

Al–Hamoudi²

2021

Advances in Hepatology

View full text Add to dashboard Cite

End-stage liver disease secondary to hepatitis C virus (HCV) infection is a major indication for liver transplantation (LT) worldwide. Previous studies have shown a negative impact of HCV on patient and graft survival leading to an inferior transplant outcome when compared to other liver transplant indications. The percentage of HCV patients infected with genotype 4 (G4) among recipients of OLT varies depending on geographic location. In the Middle East HCV-G4 infection is the most common genotype among transplant recipients. Direct antiviral agents (DAAs) have revolutionized the management of HCV infection in the pre- and post-transplant setting. Recent clinical trials have shown high sustained virologic response rates, shorter durations of treatment, and decreased adverse events when compared with the previous treatment of pegylated interferon (PEG-IFN)-based therapy. However, most of these studies were performed in HCV-G1-infected patients. Due to the low prevalence of HCV-G4 in Europe and the USA, this genotype has not been adequately studied in prospective trials evaluating treatment outcomes. The aim of this chapter is to summarize the natural history and treatment outcome of HCV-G4 in the liver transplant setting, with particular attention to new HCV therapies.

show abstract

“…The overall SVR rates in the two groups were 98. 1% [136]. In another study, patients who failed SOF/DCV were retreated successfully with other DAAs [137].…”

Section: Daa Treatment Failuresmentioning

confidence: 98%

Liver Transplantation and HCV Genotype 4

Alghamdi¹,

Al–Hamoudi²

2021

Advances in Hepatology

View full text Add to dashboard Cite

show abstract

Fibrosis Stage-specific Incidence of Hepatocellular Cancer After Hepatitis C Cure With Direct-acting Antivirals: A Systematic Review and Meta-analysis

Kim

Vutien

Cleveland

et al. 2023

Clinical Gastroenterology and Hepatology

View full text Add to dashboard Cite

Development and validation of a novel bioanalytical method for the simultaneous determination of glecaprevir and pibrentasvir in human plasma using reversed-phase high-performance liquid chromatography

Narender

Pavani

Prasanth

et al. 2022

Egyptian Pharmaceutical Journal

View full text Add to dashboard Cite

Background and objective For the simultaneous determination of glecaprevir (GPR) and pibrentasvir (PTR) in human plasma, a novel, accurate, and selective reversed-phase high-performance liquid chromatography method was developed and validated. Materials and methods Owing to structural resemblance, bictegravir was selected as an internal standard. Anticoagulant used was K2-EDTA. The GPR-PTR was the first of its kind approved drug by FDA for the treatment of chronic hepatitis C. Precipitation technique with acetonitrile was employed for the extraction of analyte from human plasma. Kromasil C18 column (5 μ, 150×4.6 mm) with an isocratic mobile phase of 0.1% orthophosphoric acid buffer pH 4.3, adjusted with dilute hydrochloric acid: acetonitrile in the ratio of 70 : 30 v/v, was used for the resolution. At a flow rate of 1 ml/min, the mobile phase was pumped. Using a photodiode array detector, effluents were monitored at 250 nm. Results Over concentration ranges of 5–200 μg/ml and 6.650–266.000 μg/ml, the method was found to be linear for GPR and PTR, respectively, in human plasma, with the precision and accuracy ranging from 0.76 to 9.05% and 90.55 to 98.98% for GPR respectively, whereas for PTR ranged from 0.74 to 9.52% and 91.56 to 105.61%, respectively. Conclusion The stability of the analyte was evaluated in plasma under different stress conditions.

show abstract

Real‐world safety and effectiveness of retreatment of Egyptian chronic hepatitis C patients not responding to NS5A inhibitor‐based therapies

Cited by 3 publications

References 31 publications

Liver Transplantation and HCV Genotype 4

Liver Transplantation and HCV Genotype 4

Fibrosis Stage-specific Incidence of Hepatocellular Cancer After Hepatitis C Cure With Direct-acting Antivirals: A Systematic Review and Meta-analysis

Development and validation of a novel bioanalytical method for the simultaneous determination of glecaprevir and pibrentasvir in human plasma using reversed-phase high-performance liquid chromatography

Contact Info

Product

Resources

About